Reuters logo
BRIEF-Adaptimmune says provides update on clinical study
October 12, 2016 / 1:27 PM / a year ago

BRIEF-Adaptimmune says provides update on clinical study

Oct 12 (Reuters) - Adaptimmune Therapeutics Plc

* Adaptimmune provides update on clinical study evaluating its spear t-cell therapy targeting ny-eso-1 in ovarian cancer

* Says amended protocol using its ny-eso spear t-cell therapy in ovarian cancer patients now actively recruiting

* Says the multi-center study is intended to enroll up to 10 additional patients under revised protocol

* Says no objective clinical responses reported in ovarian cancer patients who received t-cell therapy in trial’s initial iteration

* Says trial to enroll patients under revised protocol including pre-conditioning regimen that includes fludarabine, cyclophosphamide Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below